CHRISTOPHER MILLER: Open Payments
NPI 1306467311 · LAKELAND, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,524 in 235 payments from 19 companies in 2025. Trend: 2023 $3,446 · 2024 $3,058 · 2025 $4,524
Food & beverage: $4,524
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 20 | $441 |
| Neurocrine BioSciences, Inc. | 19 | $410 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $400 |
| Axsome Therapeutics, Inc. | 16 | $371 |
| Noven Therapeutics, LLC | 20 | $362 |
| Otsuka America Pharmaceutical, Inc. | 13 | $342 |
| ABBVIE INC. | 20 | $339 |
| Alkermes, Inc. | 14 | $314 |
| Lundbeck LLC | 8 | $232 |
| Tris Pharma Inc | 19 | $218 |
Products named: REXULTI, INGREZZA, CAPLYTA, Xelstrym, FANAPT, ARISTADA, VRAYLAR, Auvelity.
Industry payments across FL — which companies pay providers there.
